Synergistic Cancer Therapy: An NIR-Activated Methylene Blue-Nitrogen Mustard Prodrug for Combined Chemotherapy and...

Area of Science:

• Oncology
• Biomedical Engineering
• Photochemistry

Background:

• Nitrogen mustard is an effective chemotherapy drug but lacks tumor selectivity and causes severe side effects.
• Developing targeted drug delivery systems is crucial for improving cancer therapy efficacy and reducing toxicity.

Purpose of the Study:

• To develop a near-infrared (NIR)-activatable nitrogen mustard prodrug (MBNM) for enhanced cancer treatment.
• To investigate the synergistic effects of combining chemotherapy and photodynamic therapy (PDT) using MBNM.
• To evaluate the biosafety and real-time monitoring capabilities of the MBNM prodrug system.

Main Methods:

• Synthesis and characterization of the MBNM prodrug.
• NIR irradiation to activate MBNM and induce release of nitrogen mustard and methylene blue (MB).
• In vitro and in vivo studies to assess tumor suppression, drug release, and biosafety.

Main Results:

• MBNM demonstrated controlled release of nitrogen mustard and MB upon NIR irradiation.
• The combination therapy showed synergistic tumor suppression.
• MBNM exhibited significantly improved biosafety compared to free nitrogen mustard.
• MB release allowed for real-time monitoring of prodrug activation.

Conclusions:

• The photocleavable prodrug MBNM offers a promising strategy for safe and effective combination cancer therapy.
• NIR-activated MBNM enables synergistic chemotherapy and PDT with enhanced biosafety.
• Real-time monitoring of prodrug activation is achievable with the MB component.